Biofrontera Net Worth
Biofrontera Net Worth Breakdown | BFRI |
Biofrontera Net Worth Analysis
Biofrontera's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biofrontera's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biofrontera's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biofrontera's net worth analysis. One common approach is to calculate Biofrontera's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biofrontera's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biofrontera's net worth. This approach calculates the present value of Biofrontera's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biofrontera's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biofrontera's net worth. This involves comparing Biofrontera's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biofrontera's net worth relative to its peers.
Enterprise Value |
|
To determine if Biofrontera is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biofrontera's net worth research are outlined below:
| Biofrontera generated a negative expected return over the last 90 days | |
| Biofrontera has high historical volatility and very poor performance | |
| Biofrontera has some characteristics of a very speculative penny stock | |
| Biofrontera has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 34.07 M. Net Loss for the year was (20.13 M) with profit before overhead, payroll, taxes, and interest of 13.49 M. | |
| Biofrontera currently holds about 31.91 M in cash with (24.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biofrontera has a frail financial position based on the latest SEC disclosures | |
| Roughly 32.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Hermann Luebbert of 190840 shares of Biofrontera subject to Rule 16b-3 |
Biofrontera uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biofrontera. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biofrontera's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Biofrontera's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biofrontera is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biofrontera backward and forwards among themselves. Biofrontera's institutional investor refers to the entity that pools money to purchase Biofrontera's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-06-30 | 11.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Hrt Financial Llc | 2024-06-30 | 0.0 | Aigh Capital Management, Llc | 2024-09-30 | 501.4 K | Rosalind Advisors, Inc. | 2024-09-30 | 495.5 K | Scotia Capital Inc | 2024-06-30 | 120 K | Geode Capital Management, Llc | 2024-09-30 | 17.1 K | Tower Research Capital Llc | 2024-06-30 | 10.5 K | Ubs Group Ag | 2024-06-30 | 10 K | Blackrock Inc | 2024-06-30 | 4.6 K |
Follow Biofrontera's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.67 M.Market Cap |
|
Project Biofrontera's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.80) | (0.84) | |
| Return On Capital Employed | (2.30) | (2.19) | |
| Return On Assets | (0.72) | (0.76) | |
| Return On Equity | (4.20) | (3.99) |
When accessing Biofrontera's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biofrontera's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biofrontera's profitability and make more informed investment decisions.
Evaluate Biofrontera's management efficiency
Biofrontera has return on total asset (ROA) of (0.4024) % which means that it has lost $0.4024 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4941) %, meaning that it created substantial loss on money invested by shareholders. Biofrontera's management efficiency ratios could be used to measure how well Biofrontera manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.84. The Biofrontera's current Return On Capital Employed is estimated to increase to -2.19. As of now, Biofrontera's Total Current Assets are increasing as compared to previous years. The Biofrontera's current Intangible Assets is estimated to increase to about 2.8 M, while Non Currrent Assets Other are projected to decrease to under 457.9 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.10 | 3.25 | |
| Tangible Book Value Per Share | 1.40 | 1.47 | |
| Enterprise Value Over EBITDA | (0.45) | (0.47) | |
| Price Book Value Ratio | 0.89 | 0.85 | |
| Enterprise Value Multiple | (0.45) | (0.47) | |
| Price Fair Value | 0.89 | 0.85 | |
| Enterprise Value | 8.3 M | 7.9 M |
The strategic initiatives led by Biofrontera's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.1439 | Revenue 35.2 M | Quarterly Revenue Growth 0.34 | Revenue Per Share 11.573 | Return On Equity (1.49) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biofrontera insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biofrontera's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biofrontera insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hermann Luebbert 2 days ago Acquisition by Hermann Luebbert of 190840 shares of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over six months ago Disposition of 4771 shares by Hermann Luebbert of Biofrontera subject to Rule 16b-3 | ||
Wedge Loretta M. over six months ago Insider Trading | ||
Luebbert Hermann over a year ago Exercise or conversion by Luebbert Hermann of 95420 shares of Biofrontera subject to Rule 16b-3 |
Biofrontera Earnings per Share Projection vs Actual
Biofrontera Corporate Management
| Daniel JD | General Compliance | Profile | |
| Jon MBA | Vice Affairs | Profile | |
| Erica CPA | COO, CEO | Profile | |
| Jeff Holm | Head Devel | Profile | |
| Mark Baldyga | Head Marketing | Profile | |
| Alycia Torres | Vice Administration | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.16 | Revenue Per Share 11.573 | Quarterly Revenue Growth 0.34 | Return On Assets (0.40) | Return On Equity (1.49) |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.